🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Cascade Pharmaceuticals clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Cascade Pharmaceuticals as lead sponsor. Synced 26 Sep 2026
6Current trials
2Recruiting now
3Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Cascade Pharmaceuticals is the lead sponsor of 6 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are CS0159, CS060380 and Semaglutide. The most-studied condition is Metabolic Dysfunction-associated Steatohepatitis (MASH).

ClinicalTrials.gov trials by status

  • Recruiting233%
  • Active, closed467%

Trials by phase

  • Phase 2467%
  • Phase 3117%
  • Phase 1117%
01

Clinical trials sponsored by Cascade Pharmaceuticals

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
NCT07282353 · ClinicalTrials.gov ↗ · Primary Biliary Cholangitis
Drug: CS0159
Phase 3 Recruiting 2025-12 China
Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)
NCT07198386 · ClinicalTrials.gov ↗ · NASH
Drug: CS060380
Phase 2 Recruiting 2025-09 China
A Study of CS060380 Tablets in Patients With MASH and Obesity
NCT07466017 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity
Phase 2 Active, closed 2026-04 China
CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
NCT05896124 · ClinicalTrials.gov ↗ · Primary Biliary Cholangitis (PBC)
Drug: CS0159
Phase 2 Active, closed 2023-08 China
CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
NCT05896137 · ClinicalTrials.gov ↗ · Primary Sclerosing Cholangitis
Drug: CS0159
Phase 2 Active, closed 2023-08 China
Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects
NCT06485245 · ClinicalTrials.gov ↗ · MASH
Phase 1 Active, closed 2025-04 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Cascade Pharmaceuticals trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Cascade Pharmaceuticals trials

7 conditions
Metabolic Dysfunction-associated Steatohepatitis (MASH)1Obesity1Primary Biliary Cholangitis (PBC)1Primary Sclerosing Cholangitis1Primary Biliary Cholangitis1MASH1NASH1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China62

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Metabolic Dysfunction-associated Steatohepatitis (MASH)

SponsorTrials
The Cleveland Clinic1
Changchun Intellicrown Pharmaceutical1
Kriya Therapeutics1
The United Bio-Technology (Hengqin)1

Sponsors with the most current trials registered for this condition.

06

Questions about Cascade Pharmaceuticals trials

How many clinical trials does Cascade Pharmaceuticals sponsor?

Cascade Pharmaceuticals is the lead sponsor of 6 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Cascade Pharmaceuticals trials recruiting?

Yes. 2 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Cascade Pharmaceuticals testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are CS0159 (3), CS060380 (2) and Semaglutide (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.